A detailed history of Meiji Yasuda Asset Management CO Ltd. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Meiji Yasuda Asset Management CO Ltd. holds 1,986 shares of ALNY stock, worth $490,144. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,986
Previous 2,030 2.17%
Holding current value
$490,144
Previous $493,000 10.75%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$233.81 - $287.01 $10,287 - $12,628
-44 Reduced 2.17%
1,986 $546,000
Q2 2024

Aug 12, 2024

BUY
$143.31 - $247.0 $38,693 - $66,690
270 Added 15.34%
2,030 $493,000
Q1 2024

May 15, 2024

BUY
$146.51 - $198.2 $55,673 - $75,316
380 Added 27.54%
1,760 $263,000
Q3 2023

Nov 13, 2023

BUY
$170.77 - $211.65 $27,323 - $33,864
160 Added 13.11%
1,380 $244,000
Q1 2023

May 09, 2023

BUY
$182.66 - $235.53 $9,133 - $11,776
50 Added 4.27%
1,220 $244,000
Q4 2022

Feb 14, 2023

SELL
$185.53 - $241.31 $9,276 - $12,065
-50 Reduced 4.1%
1,170 $278,000
Q3 2022

Nov 14, 2022

SELL
$138.54 - $232.0 $26,322 - $44,080
-190 Reduced 13.48%
1,220 $244,000
Q2 2022

Aug 16, 2022

BUY
$120.42 - $169.29 $19,267 - $27,086
160 Added 12.8%
1,410 $206,000
Q1 2022

May 17, 2022

SELL
$127.18 - $173.91 $19,077 - $26,086
-150 Reduced 10.71%
1,250 $204,000
Q4 2021

Feb 14, 2022

BUY
$159.56 - $209.29 $25,529 - $33,486
160 Added 12.9%
1,400 $237,000
Q3 2021

Nov 12, 2021

BUY
$169.75 - $207.73 $10,185 - $12,463
60 Added 5.08%
1,240 $234,000
Q2 2021

Aug 13, 2021

BUY
$128.63 - $176.89 $151,783 - $208,730
1,180 New
1,180 $200,000
Q3 2020

Nov 12, 2020

SELL
$121.19 - $165.49 $178,149 - $243,270
-1,470 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$104.21 - $156.44 $153,188 - $229,966
1,470 New
1,470 $218,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.4B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Meiji Yasuda Asset Management CO Ltd. Portfolio

Follow Meiji Yasuda Asset Management CO Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meiji Yasuda Asset Management CO Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Meiji Yasuda Asset Management CO Ltd. with notifications on news.